Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026

Amneal Pharmaceuticals (AMRX)

Nasdaq Health Care Pharmaceuticals S&P SmallCap 600
$20.14
+0.69 (+3.55%)
Close of Nov 06, 2026 · end-of-day data
Source: Amneal Pharmaceuticals's 10-K / 10-Q XBRL data on SEC EDGAR · fetched Nov 03, 2026

Revenue, net income & free cash flow

Income statement

fiscal years · USD
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue$1.02B$1.03B$1.66B$1.63B$1.99B$2.09B$2.21B$2.39B$2.79B$3.02B
Cost of revenue$420.77M$507.48M$938.77M$1.15B$1.33B$1.32B$1.43B$1.57B$1.77B$1.91B
Gross profit$597.46M$526.18M$716.40M$353.00M$628.39M$768.97M$784.71M$820.57M$1.02B$1.11B
Research & development$179.02M$171.42M$194.19M$188.05M$179.93M$201.85M$195.69M$163.95M$190.71M$186.18M
Selling, general & admin$118.76M$109.05M$227.85M$289.60M$326.73M$365.50M$399.70M$429.68M$476.44M$526.83M
Operating income$284.88M$245.10M-$19.67M-$248.68M$91.16M$152.72M-$94.93M$204.37M$249.33M$394.10M
Pre-tax income$214.82M$171.32M-$202.72M-$220.24M-$35.78M$31.37M-$248.13M-$40.27M-$55.01M$139.21M
Income tax$5.39M$2.00M-$1.42M$383.33M-$104.36M$11.20M$6.66M$8.45M$18.86M$11.28M
Net income$0$0-$19.74M-$603.57M$67.79M$13.16M-$270.58M-$83.99M-$116.89M$72.06M
EBITDA$314.19M$287.06M$44.74M-$185.40M$151.57M$213.42M-$26.83M$270.57M$311.93M$451.40M
EPS (basic)——$-0.16$-2.74$0.62$0.07$-0.86$-0.48$-0.38$0.23
EPS (diluted)——$-0.16$-2.74$0.61$0.07$-0.86$-0.48$-0.38$0.22
Diluted shares——127.25M132.11M148.91M151.82M150.94M176.14M308.98M324.81M
Gross margin58.7%50.9%43.1%21.7%31.5%36.7%35.5%34.3%36.5%36.9%
Operating margin28.0%23.7%-1.2%-15.3%4.6%7.3%-4.3%8.5%8.9%13.1%
Net margin0.0%0.0%-1.2%-37.1%3.4%0.6%-12.2%-3.5%-4.2%2.4%

Balance sheet

fiscal years · USD
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash & equivalents$27.37M$74.17M$213.39M$151.20M$341.38M$247.79M$25.98M$91.54M$110.55M$282.03M
Receivables—$351.37M$481.50M$604.39M$638.89M$662.58M$741.79M———
Inventory—$284.04M$457.22M$381.07M$490.65M$489.39M$530.74M$581.38M$612.45M$606.30M
Total current assets—$771.93M$1.29B$1.21B$1.55B$1.52B$1.41B$1.38B$1.59B$1.91B
Goodwill$28.44M$26.44M$426.23M$419.50M$522.81M$593.02M$598.85M$598.63M$597.44M$595.47M
Total assets—$1.34B$4.35B$3.67B$4.01B$3.94B$3.80B$3.47B$3.50B$3.68B
Total current liabilities—$296.88M$553.85M$550.41M$676.90M$677.24M$752.80M$846.60M$1.13B$881.63M
Short-term debt—$89.17M$21.45M$21.48M$44.23M$30.61M$29.96M$34.12M$224.21M$6.76M
Long-term debt—$1.36B$2.63B$2.61B$2.74B$2.68B$2.59B$2.39B$2.16B$2.57B
Total debt—$1.44B$2.65B$2.63B$2.78B$2.71B$2.62B$2.42B$2.39B$2.57B
Total liabilities—$0$3.85B$3.43B$3.70B$3.58B$3.50B$3.45B$3.61B$3.75B
Shareholders' equity—$0$504.75M$232.01M$303.27M$360.34M$298.42M$19.78M-$109.27M-$70.79M

Cash flow

fiscal years · USD
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow$115.06M$234.19M$250.23M$1.71M$379.00M$241.82M$65.10M$345.58M$295.10M$339.99M
Capital expenditures$122.76M$94.77M$83.09M$47.18M$56.45M$47.73M$46.41M$43.22M$51.92M$70.06M
Free cash flow-$7.70M$139.42M$167.14M-$45.48M$322.56M$194.09M$18.69M$302.36M$243.18M$269.93M
Investing cash flow-$124.61M-$98.55M-$396.38M-$19.58M-$317.55M-$194.18M-$174.31M-$69.19M-$63.00M-$112.26M
Financing cash flow-$19.50M-$95.02M$287.68M-$45.83M$131.81M-$138.12M-$106.62M-$212.57M-$211.79M-$31.53M
Dividends paid$200.62M$375.26M$183.00M$0$0—————
Stock-based compensation$0$0$167.60M$21.68M$20.75M$28.41M$31.85M$26.82M$27.77M$31.95M
Depreciation & amortization$29.31M$41.96M$64.42M$63.28M$60.42M$60.70M$68.10M$66.20M$62.60M$57.30M

Quarterly figures are rebuilt from the year-to-date totals companies report — Q4 is the full year minus the first nine months, since no 10-Q is filed for it. Values are as filed; later restatements replace earlier ones. Fiscal years are labelled by the calendar year in which they end.